501 Canal Boulevard
About Sangamo Therapeutics
Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
516 articles with Sangamo Therapeutics
Sangamo Therapeutics, Inc. announced that the Company will release its first quarter 2019 financial results after the market closes on Wednesday, May 8, 2019.
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - April 8, 2019
Sangamo Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock.
The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
Conference call and webcast scheduled for 8:00 a.m. Eastern Time
Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio
Balanced in-house and contract manufacturing strategy to provide clinical and commercial supply for Sangamo's growing pipeline of AAV-based genomic therapies
Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on Tuesday, April 2nd at 8:00 a.m. Eastern Time to provide a clinical development update.
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
Data presented at ADPD show that tau-targeted ZFP-TFs delivered with AAVs in mice and nonhuman primates have significant activity
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
3/22/2019Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
Sangamo Therapeutics, Inc., a genomic medicine company, announced the appointment of Jason Fontenot, Ph.D., as Senior Vice President, Cell Therapy.
Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
Data published in Nature Communications show new architectures increase targeting capabilities by 64-fold
Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will participate in the following healthcare investor conferences in March
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
Sangamo Therapeutics, Inc., a genomic medicine company, announced that the Company will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, February 28, 2019.
Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease
Shares of Brisbane, Calif.-based Sangamo Therapeutics plunged 30 percent Thursday after the company released preliminary results from a gene-editing trial that investors saw as less than stellar.
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
- Liver biopsy analysis detected targeted integration of IDS transgene, providing preliminary molecular evidence of in vivo genome editing in humans